Developments in Scanning Electron Microscopy for Tablet and Granule Characterization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Developments in Scanning Electron Microscopy for Tablet and Granule Characterization
Recent advances in SEM, particularly the incorporation of automation and software, have made simpler, lower-end SEM instruments easy to operate and have improved the capabilities of larger, sophisticated instruments.


Pharmaceutical Technology



FEI COMPANY
Scanning electron microscopy (SEM) provides a qualitative assessment of size, shape, morphology, porosity, size distribution, crystal form, and consistency of powders or compressed dosage forms (see Figure 1). This information can be correlated to assess dissolution behavior, bioavailability, and crystalline structure. SEM images also help analysts determine whether particles are maintaining desired physical characteristics during processing, including after compaction or direct compression (see Figures 2, 3).


Figure 1: (FIGURE COURTESY OF FEI COMPANY)
As an analytical tool, electron microscopy in general has changed extensively, especially with the incorporation of automation and software. An SEM instrument in the 1940s, for example, had a resolving power of about 50 nm and a magnification of 8000. Today, SEM devices have resolving power of 1 nm and a magnification as high as 400,000 (1). Simple, low-end SEM instruments now have touchscreen user interfaces and provide a fast visual inspection of samples. On the very high end, transmission electron microscopes have recently demonstrated the capability to identify individual atoms (2).


Microscopy advances
"Commonly called the laboratory 'workhorse,' microscopes have come a long way to the present day in terms of advancements in automation, higher precision, and better resolution," says Sharon Mathews, a research associate for Technical Insights at Frost & Sullivan. "With digital imaging gaining momentum in the recent years, microscope manufactures are now designing microscopes with image analysis at the forefront" (see sidebar, "Microscopy advances").






Figure 2: (FIGURE COURTESY OF FEI COMPANY)
Mathews attributes the following factors as primary drivers to increasing use of microscopy:
  • Innovations in digital imaging: "Digital imaging offers numerous capabilities to the microscopy market opportunities in terms of enhanced features to extract information or modify the images captured. The convergence of digital imaging and information technology is enabling microscope manufacturers in tailoring their product offerings to suit the specific requirements."
  • Cost effectiveness and ease of operation: "With the diversity of the end-user and lower cost, the microscopy market is steadily growing. Simple automated systems are now increasing the usage of microscopes."
  • Novel applications: "The clinical market, namely, pathology, cytology, and hematology have greatly relied on microscopy over the years. Owing to new imaging applications and research funding, the pharmaceutical, academic, and government laboratories are now propelling the microscopy market. Live cell imaging, molecular imaging enabling identification of events at molecular level and specific applications such as dynamic behavior of cells ... has been responsible for the rapid progress of the microscopy market" (3).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here